Clinical Trials for Mesothelioma Patients: NGR-hTNF as Single Agent
Read about a current clinical trial being conducted to study NGR-hTNF as a single agent in patients who have been diagnosed with mesothelioma. At this time, the study is only being conducted in Italy. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma (NGR010)
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.
Safety will be established by clinical and laboratory assessment according to NCI-CTC criteria.Requisite Conditions:
Study Phase, Type and Design:
Phase II Interventional; Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study
NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen
If you or a loved one has been doagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.